Vigilant Biosciences® Leads the Charge Against Oral Cancer

Lakeway, Texas (Oct. 4, 2023) – Vigilant Biosciences®, Inc. (“Vigilant”), an industry-leading developer of cutting-edge solutions that accelerate the detection of oral cancer, announces the release of its flagship product, the BeVigilant™ OraFusion™ System, in Italy.

The BeVigilant™ OraFusion™ System is a breakthrough device that administers an oral cancer risk assessment at the point of care. The system provides an accurate risk assessment result through the combined analysis of early-stage biomarker concentrations and intelligent software powered clinical risk factor evaluation. This integrated analysis equips frontline clinicians with the necessary data to make informed treatment decisions for patients with oral lesions.

“From the start, Vigilant has aimed to increase the oral cancer survival rate through early detection and intervention,” said Bill Brodie, CEO of Vigilant Biosciences®. “The BeVigilant™ OraFusion™ System is bringing this goal to fruition, helping clinicians in the assessment of oral cancer to detect it earlier than ever before. By taking the next step in reshaping oral cancer detection, we believe our technology will bring hope and life-saving outcomes to those impacted by this disease.”

When patients are referred to specialized care during the early stages of oral cancer, treatment is often less invasive and more effective, leading to significantly improved outcomes. The current oral cancer survival rate is 50%, but early detection can substantially increase the survival rate up to 90%.

Vigilant Biosciences® continues to blaze the trail in the fight against oral cancer with simple, accurate, and cost-effective solutions that empower early detection, effective intervention, and better outcomes. For more information on Vigilant Biosciences® and its products, please visit

Note: The BeVigilant™ OraFusion™ System is not available for sale in the U.S.

About Vigilant Biosciences®, Inc.
Vigilant Biosciences® is a leading innovator and developer of solutions that aid clinicians in the early detection of oral cancer. Vigilant’s BeVigilant™ product line includes point-of-care testing that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. Learn more about Vigilant Biosciences® at